secwatch.observer — SEC 8-K summary
======================================

Issuer:     Silexion Therapeutics Corp (SLXN)
CIK:        0002022416
Form:       8-K
Filed at:   2026-03-23T23:59:59+00:00
Accession:  0001178913-26-001597
Event type: other_material
Sentiment:  negative
Materiality: 0.15
Item codes: 5.07
LLM model:  deepseek-v4-flash:cloud@v2

Silexion Therapeutics shareholders vote down share capital increase and equity plan expansion
--------------------------------------------------------------------------------

- At reconvened EGM on March 23, 2026, quorum met with 1,216,369 shares (36.6% of outstanding).
- Proposal to increase authorized shares from 9M to 59M failed: 38.2% for, 61.8% against.
- Proposal to expand evergreen provision of 2024 equity plan to 10% fully diluted failed: 40.7% for, 59.3% against.
- Neither proposal received the simple majority required for approval.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/2022416/000117891326001597/0001178913-26-001597-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/2022416/000117891326001597/zk2634902.htm
  HTML page:      https://secwatch.observer/filing/0001178913-26-001597

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer